CD163 and glioblastoma: It was discovered through this platform that in comparison with proneural GBM, glioblastomas affecting the mesenchymal niche attracted significantly higher levels of CD163+ M2 TAMs and PD‐1/PD‐L1 and responded better to ICI treatment.99